Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.97 USD
Change Today +0.28 / 4.19%
Volume 279.4K
TRVN On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $8.16
52 Week Low
12/9/14 - $3.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment-refractory migraine headaches. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase II clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

42 Employees
Last Reported Date: 03/18/15
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $532.6K
Chief Medical Officer
Total Annual Compensation: $376.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $441.4K
Compensation as of Fiscal Year 2013.

trevena inc (TRVN) Key Developments

Trevena, Inc. Announces Unaudited Earnings Results for the Year Ended December 31, 2014

Trevena, Inc. announced unaudited earnings results for the year ended December 31, 2014. For the period, the company loss from operations was $49,949,920 against $23,345,286 a year ago. Net loss was $49,700,875 against $23,251,435 a year ago. Net loss attributable to common stockholders was $49,729,396 against $23,585,145 a year ago. Net loss per share of common stock, basic and diluted was $2.02 against $29.71 a year ago. The increase in net loss attributable to common stockholders for the year ended December 31, 2014, compared to the net loss attributable to common stockholders for the same period in 2013, was primarily due to higher clinical research expenses in 2014 associated with the company’s advancement into a Phase 2b clinical trial of TRV027 and the initiation and completion of a Phase 2a/b clinical trial of TRV130, as well as increased operating costs in support of the Company’s expanded development activities.

Trevena, Inc., 2014 Earnings Call, Mar 18, 2015

Trevena, Inc., 2014 Earnings Call, Mar 18, 2015

Trevena Completes Interim Analysis and Announces Plans for Ongoing Phase 2b BLAST-AHF trial of TRV027 in Acute Heart Failure

Trevena, Inc. announced its plans for the continuation of the BLAST-AHF trial – a double-blind placebo-controlled study of TRV027 in patients with acute heart failure (AHF) – following the recent completion of the pre-specified interim analysis. Based on a review of the safety and efficacy data from 254 study patients, Trevena and Actavis have agreed to weight future enrollment toward the most promising dose and to increase target enrollment in the study from 500 patients to 620 patients. Actavis, which holds an exclusive option to license TRV027, will fully fund this expansion of the study via a $10 million payment to Trevena. The purpose of the planned interim analysis was to qualitatively and quantitatively evaluate safety and efficacy data to determine how best to allocate future patients in the study to generate the most robust data. Upon reviewing the data, the data safety monitoring board (DSMB) and the BLAST-AHF Steering Committee recommended that future enrollment be weighted to the most promising dose of 5 mg/hr. Remaining enrollment will be weighted 2:1:2:1 for placebo, 1 mg/hr, 5 mg/hr, and 25 mg/hr, respectively. In addition, the DSMB and Steering Committee determined that patients with lower baseline systolic blood pressure could safely enroll in the study; inclusion criteria have been modified accordingly. As a result of the increased target enrollment, Trevena now expects to release top-line data in the first half of 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $6.97 USD +0.28

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at